CAMBRIDGE, Mass.--(BUSINESS WIRE)--Compass Therapeutics, a clinical-stage biotechnology company focused on drugging the human immune synapse to treat human diseases, today announced two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting, which is being held November 6-10 in National Harbor, MD.
The first poster will show recent data on CTX-8371, a novel bispecific antibody targeting the inhibitory receptor PD-1 and its ligand, PD-L1. CTX-8371 was discovered in an unbiased screen of checkpoint bispecifics using Compass’s proprietary StitchMabsTM technology. CTX- 8371 demonstrates significantly increased potency in vitro and in vivo compared to combinations of monoclonals blocking PD-1 and PD-L1. Mechanistic studies of CTX-8371 suggest that the enhanced potency is associated with its unique ability to drive PD-1 downregulation from the surface of effector T cells.
The second poster presentation describes Compass’s innate-cell engager platform. Leveraging its common light-chain technology, Compass has developed a series of bispecific antibodies that simultaneously engage tumor associated antigens and the activating receptor NKp30 expressed on NK cells and other innate effector cells to promote potent and highly selective tumor cell killing.
Full details of the presentations are as follows:
Poster title: CTX-8371, a novel bispecific targeting both PD-1 and PD-L1, is more potent than combination anti-PD-1 and PD-L1 therapy and provides enhanced protection from tumors in vivo
Abstract ID: P251
Date & time: Friday, Nov. 8, 7:00 am - 8:00 pm ET
Location: Poster Hall (Prince George AB), Gaylord National Hotel & Convention Center, National Harbor, Md.
Poster title: A novel class of multi-specific antibodies targeting NKp30 on innate immune cells
Abstract ID: P7770
Date & time: Saturday, Nov. 9, 7:00 am - 8:00 pm ET
Location: Poster Hall (Prince George AB), Gaylord National Hotel & Convention Center, National Harbor, Md.
About Compass Therapeutics
Compass Therapeutics is a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics. Compass has broadly drugged the immune system by generating epitopically diverse antibody panels to more than 40 targets across all immune cell types and is leveraging its proprietary StitchMabsTM and common light-chain based multispecific platforms to empirically identify combinations and multispecifics with optimized activity. The company’s lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, which is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors. Compass is also progressing several preclinical assets including a novel class of innate-cell engaging bispecifics targeting NKp30 and multiple bispecific checkpoint programs. The company’s offices and labs are based in Kendall Square in Cambridge, Mass.
